Alec Stranahan
Stock Analyst at B of A Securities
(0.84)
# 3,959
Out of 5,044 analysts
31
Total ratings
41.67%
Success rate
-23.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $189.65 | +34.46% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.60 | +25.00% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $14.25 | -15.79% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $2.44 | -59.02% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.52 | -17.84% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $26.43 | +58.91% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.33 | +241.06% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $2.47 | +345.34% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.87 | +109.06% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $3.17 | +373.19% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $58.17 | -5.45% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $34.55 | -82.63% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $189.65
Upside: +34.46%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.60
Upside: +25.00%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $14.25
Upside: -15.79%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $2.44
Upside: -59.02%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.52
Upside: -17.84%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $26.43
Upside: +58.91%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.33
Upside: +241.06%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $2.47
Upside: +345.34%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.87
Upside: +109.06%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.17
Upside: +373.19%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $58.17
Upside: -5.45%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $34.55
Upside: -82.63%